| pubmed-article:19824668 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19824668 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:19824668 | lifeskim:mentions | umls-concept:C1948023 | lld:lifeskim |
| pubmed-article:19824668 | lifeskim:mentions | umls-concept:C0032521 | lld:lifeskim |
| pubmed-article:19824668 | lifeskim:mentions | umls-concept:C1331096 | lld:lifeskim |
| pubmed-article:19824668 | lifeskim:mentions | umls-concept:C0006935 | lld:lifeskim |
| pubmed-article:19824668 | lifeskim:mentions | umls-concept:C0063083 | lld:lifeskim |
| pubmed-article:19824668 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:19824668 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:19824668 | pubmed:dateCreated | 2009-11-25 | lld:pubmed |
| pubmed-article:19824668 | pubmed:abstractText | Successful delivery of labile vaccine antigens, such as peptides and proteins, to stimulate CD4 and CD8 T cell immunity could improve vaccine strategies against chronic infections such as HIV and Hepatitis C. Layer-by-layer (LbL)-assembled nanoengineered hydrogel capsules represent a novel and promising technology for the protection and delivery of labile vaccine candidates to antigen-presenting cells (APCs). Here we report on the in vitro and in vivo immunostimulatory capabilities of LbL-assembled disulfide cross-linked poly(methacrylic acid) (PMA(SH)) hydrogel capsules as a delivery strategy for protein and peptide vaccines using robust transgenic mice models and ovalbumin (OVA) as a model vaccine. We demonstrate that OVA protein as well as multiple OVA peptides can be successfully encapsulated within nanoengineered PMA(SH) hydrogel capsules. OVA-containing PMA(SH) capsules are internalized by mouse APCs, resulting in presentation of OVA epitopes and subsequent activation of OVA-specific CD4 and CD8 T cells in vitro. OVA-specific CD4 and CD8 T cells are also activated to proliferate in vivo following intravenous vaccination of mice with OVA protein- and OVA peptide-loaded PMA(SH) hydrogel capsules. Furthermore, we show that OVA encapsulated within the PMA(SH) capsules resulted in at least 6-fold greater proliferation of OVA-specific CD8 T cells and 70-fold greater proliferation of OVA-specific CD4 T cells in vivo compared to the equivalent amount of OVA protein administered alone. These results highlight the potential of nanoengineered hydrogel capsules for vaccine delivery. | lld:pubmed |
| pubmed-article:19824668 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19824668 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19824668 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19824668 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19824668 | pubmed:issn | 1936-086X | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:BrooksAndrew... | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:CarusoFrankF | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:KentStephen... | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:ZelikinAlexan... | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:SextonAmyA | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:JohnstonAngus... | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:WhitneyPaul... | lld:pubmed |
| pubmed-article:19824668 | pubmed:author | pubmed-author:ChongSiow-Fen... | lld:pubmed |
| pubmed-article:19824668 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19824668 | pubmed:day | 24 | lld:pubmed |
| pubmed-article:19824668 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:19824668 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19824668 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19824668 | pubmed:pagination | 3391-400 | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:meshHeading | pubmed-meshheading:19824668... | lld:pubmed |
| pubmed-article:19824668 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19824668 | pubmed:articleTitle | A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. | lld:pubmed |
| pubmed-article:19824668 | pubmed:affiliation | Department of Microbiology & Immunology, The University of Melbourne, Parkville, Victoria, Australia. | lld:pubmed |
| pubmed-article:19824668 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19824668 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
